Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus LOCAMETZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus LOCAMETZ.
COR-OTICIN vs LOCAMETZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Metformin hydrochloride is a biguanide antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes mellitus. It primarily decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
1-2 drops in each affected ear twice daily for 7 days.
Locametz (gallium Ga 68 gozetotide) is administered intravenously at a dose of 3-5 mCi (110-185 MBq) as a single injection for PET imaging. No repeated dosing schedule is defined.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life of 14 hours (range 12-16 h); clinically, steady-state achieved after 3 days.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal excretion (70% unchanged), with 20% fecal elimination via biliary secretion; 10% metabolized.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid